LLY · Full Picture

ELI LILLY & Co — the full picture

Earnings window · 2026-04-30 to 2026-09-24 · anchored on the 10-Q report

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Revenue Performance and Mix · Revenue growth & mixPriority 93
    +35.7% revenue (realized); 4 sources (news, press_release, sec_filing, transcript); 3 forward row(s); quote_verified
    Eli Lilly reported Q1 2026 revenue increased 56% year-over-year to $19.8 billion and non-GAAP diluted EPS increased 156% to $8.55, and management raised full-year 2026 revenue guidance to $82 billion to $85 billion.
  2. Acquisition Activity and IPR&D · M&A and divestituresPriority 89
    -1.5% liability; 3 sources (news, sec_filing, transcript); 4 forward row(s); structured_verified
    Acquired IPR&D charges for the three months ended March 31, 2026: $1,572 million; for the three months ended March 31, 2025: $(63) million.
  3. Manufacturing capacity expansion · Supply chain & operationsPriority 88
    +8.6% assets; 4 sources (news, press_release, sec_filing, transcript); 8 forward row(s); quote_verified
    Eli Lilly broke ground on a new $6.5 billion manufacturing facility in Houston aimed at expanding GLP-1 capacity.
  4. Guidance and Outlook · Guidance & outlookPriority 85
    +9.2% revenue; 3 sources (news, press_release, sec_filing); 6 forward row(s); quote_verified
    Eli Lilly raised its full-year 2026 revenue guidance to $82 billion to $85 billion.
  5. 2026 Financial Guidance Update · Guidance & outlookPriority 82
    +9.2% revenue; 3 sources (news, press_release, transcript); 3 forward row(s); quote_verified
    Increased 2026 full-year revenue guidance to be in the range of $82.0 billion to $85.0 billion
  6. Product Revenue - Mounjaro and Zepbound · UnclassifiedPriority 81
    +16.3% revenue (realized); 4 sources (news, press_release, sec_filing, transcript); quote_verified
    Mounjaro Q1 2026 revenue increased 125% to $8,662 million worldwide
  7. Geographic Market Commentary - China & International · Geographic mixPriority 79
    +35.8% revenue (realized); 3 sources (news, press_release, transcript); quote_verified
    Revenue outside the U.S. increased 81% to $7.7 billion in Q1 2026
  8. Competition and Market Share - weight-loss · Competition & market sharePriority 77
    4 sources (news, press_release, sec_filing, transcript); 2 forward row(s); quote_verified
    Increase in U.S. volume was driven by Zepbound and Mounjaro and decline in realized prices was primarily driven by Zepbound and Taltz
  9. Acquisition / Partnership / Divestiture · M&A and divestituresPriority 76
    -1.0% cash; 4 sources (news, press_release, sec_filing, transcript); 4 forward row(s); structured_verified
    In Q2 2026, the company recognized acquired IPR&D charges of $2,776 million compared with $154 million in Q2 2025.
  10. Market Demand - Anti-Obesity · Demand, orders & backlogPriority 76
    4 sources (news, press_release, sec_filing, transcript); 1 forward row(s); quote_verified
    Company stock exceeded $1,000 per share and the company became the first pharma to surpass a $1 trillion market cap following obesity drug success, with shares having surged over 285% since 2022.
  11. Outstanding Indebtedness · Debt, leverage & refinancingPriority 75
    -15.1% liability (realized); 2 sources (news, sec_filing); 1 forward row(s); structured_verified
    In May 2026, the Company issued long-term debt totaling $9.0 billion and used net cash proceeds for general corporate purposes including repayment of outstanding commercial paper and funding portion of upfront cash consideration for acquisitions of Centessa and Kelonia.
  12. Geographic revenue shift - China NRDL · Geographic mixPriority 68
    3 sources (press_release, sec_filing, transcript); quote_verified
    The lower realized prices outside the U.S. were driven primarily by the addition of Mounjaro to the National Reimbursed Drug List (NRDL) in China

Threads by pillar

Revenue & Demand Priority 98 · 13 threads

Costs & Margins Priority 96 · 9 threads

Capital & Balance Sheet Priority 90 · 8 threads

Strategy & Portfolio Priority 97 · 12 threads

Legal, Regulatory & Policy Priority 87 · 12 threads

Guidance & Outlook Priority 88 · 2 threads

Macro & Market Conditions Priority 87 · 6 threads

Management & Governance Priority 13 · 1 thread

Shareholders & Street Priority 28 · 2 threads

Unclassified Priority 97 · 5 threads

Expected impact by metric

metricforward netforward grossrealized
cash-24.9%+24.9%-27.3%
liability-21.3%+21.3%-21.3%
assets+17.9%+19.8%+12.3%
revenue+19.7%+19.7%+87.8%
margin+3.4%+3.4%-0.6%
operating_income-0.2%+0.2%-7.3%
net_income——+23.4%